New data for Tecfidera (dimethyl fumarate) presented at ECTRIMS showing reduction in relapses and reduction of inflammation in MS patients-Biogen

Biogen will present new data that reinforce the proven efficacy and well-established safety profile of Tecfidera (dimethyl fumarate) in a broad range of people with relapsing-remitting multiple sclerosis (RRMS) at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Barcelona, Spain (7–10 October).

The data show that Tecfidera significantly reduced multiple sclerosis (MS) relapses and delayed disability progression in patients who are newly diagnosed and those early in their disease course; these effects were sustained over six years of follow-up. New data at ECTRIMS also include a post-hoc analysis in which Tecfidera significantly reduced key inflammatory disease outcomes compared to glatiramer acetate (GA) and, in a separate analysis, Tecfidera demonstrated a favourable benefit-risk profile throughout six years of follow-up from the ENDORSE study.